Previous 10 | Next 10 |
Summary Twist Bioscience share price has fallen by 50% since the beginning of 2022. Management thinks DNA data storage could be $2 billion market for the company, aided by early mover advantage and investment in IP. Twist Bioscience recently raised full-year revenue guidance, ...
ABCAM PLC First Half Trading Update Canada NewsWire CAMBRIDGE, England , July 20, 2022 /CNW/ -- Abcam plc ("Abcam", "Company", "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, today provides the following t...
Abcam: Appointment of Vice President of Investor Relations Canada NewsWire CAMBRIDGE, England , June 27, 2022 /CNW/ -- Abcam plc ("Abcam," "Company," "Group") (AIM: ABC) (Nasdaq: ABCM), a global leader in the supply of life science research tools, tod...
Abcam the most awarded company at 2022 industry awards PR Newswire CAMBRIDGE, England , March 25, 2022 /PRNewswire/ -- Abcam (AIM:ABC); (NASDAQ:ABCM), today announced that it has received six recognitions from CiteAb at their annual industry awards ...
Abcam plc (ABCM) Q4 2021 Earnings Conference Call March 14, 2022 09:00 A.M. ET Company Participants Alan Hirzel - CEO Michael S. Baldock - CFO James Stavely - VP, IR Conference Call Participants Puneet Souda - SVB Leerink Tejas Sevant - Morgan Stanley Stefan Hamill - Numis Matt Larew - Willia...
The following slide deck was published by Abcam plc in conjunction with their 2021 Q4 earnings call. For further details see: Abcam plc 2021 Q4 - Results - Earnings Call Presentation
Abcam press release (NASDAQ:ABCM): 12M net income of £47.2M Revenue of £315.4M (+17.1% Y/Y). For further details see: Abcam ADS reports FY results
Growing demand for Abcam’s portfolio of in-house products drives calendar 2021 revenues up by 22% at constant exchange rates Acquisition of BioVision completed 26 October 2021 CAMBRIDGE, United Kingdom, March 14, 2022 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: A...
Abcam to license in VHH phage library (1) from Twist, complementing in-house recombinant antibody capabilities Abcam to develop and commercialize antibodies for diagnostic and research use, with Twist retaining rights for therapeutic applications Reinforces Abcam...
Alamar Biosciences partners with Abcam to drive understanding of the human proteome Alamar selects Abcam as a key provider of antibody content for its propriety NULISA technology platform Canada NewsWire FREMONT, Calif. and CAMBRIDGE, England, Jan....
News, Short Squeeze, Breakout and More Instantly...
Danaher Completes Acquisition of Abcam PR Newswire WASHINGTON , Dec. 6, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam"). The acquisition of Abcam for $24.0...
Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, entered into a definitive agreement on August 26, 2023 relating to its proposed acquisition by Danaher Corporation (NYSE: DHR) ...
2023-11-19 06:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...